Cargando…
Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
Background: Selective progesterone receptor modulator ulipristal acetate (UPA) is a drug used in management of symptomatic myomas. It was observed that the response to UPA treatment in uterine myomas varied amongst patients. An attempt was thus made at establishing predictive factors conducive to be...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037608/ https://www.ncbi.nlm.nih.gov/pubmed/32012826 http://dx.doi.org/10.3390/ijerph17030798 |
_version_ | 1783500463815000064 |
---|---|
author | Szydłowska, Iwona Marciniak, Aleksandra Nawrocka-Rutkowska, Jolanta Rył, Aleksandra Starczewski, Andrzej |
author_facet | Szydłowska, Iwona Marciniak, Aleksandra Nawrocka-Rutkowska, Jolanta Rył, Aleksandra Starczewski, Andrzej |
author_sort | Szydłowska, Iwona |
collection | PubMed |
description | Background: Selective progesterone receptor modulator ulipristal acetate (UPA) is a drug used in management of symptomatic myomas. It was observed that the response to UPA treatment in uterine myomas varied amongst patients. An attempt was thus made at establishing predictive factors conducive to better reaction to treatment with UPA. The aim of this study was to assess the efficacy of UPA treatment in women with myomas, depending on pretreatment myomas’ volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Materials and methods: The study included patients with one to four myomas. The UPA treatment was a preparation stage for surgical treatment in all patients. The study group was divided into the subgroups according to pretreatment myomas’ volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Results: A better effect of reduction in size of myomas after UPA treatment was noted when pretreatment myomas’ volume was lower than 30 cm(3). A significant reduction in fibroids’ size was observed after UPA therapy independently of the number of myomas and age of patients. A good response after the UPA therapy was observed when pretreatment estradiol concentration was below 50 pg/mL and when uterine artery resistance index (RI) was above 0.8. Conclusions: Our research demonstrates that treatment with ulipristal acetate is an efficient method in preoperative preparation of patients with uterine fibroids. The most important factor of positive response to UPA therapy is myoma volume. The number of myomas and patient’s age do not interfere with effects of UPA therapy. Pretreatment estradiol concentration is significant, yet secondary for the effects of therapy. The UPA therapy has no impact on blood flow in the uterine arteries and no adverse influence on estradiol concentrations. |
format | Online Article Text |
id | pubmed-7037608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70376082020-03-11 Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids Szydłowska, Iwona Marciniak, Aleksandra Nawrocka-Rutkowska, Jolanta Rył, Aleksandra Starczewski, Andrzej Int J Environ Res Public Health Article Background: Selective progesterone receptor modulator ulipristal acetate (UPA) is a drug used in management of symptomatic myomas. It was observed that the response to UPA treatment in uterine myomas varied amongst patients. An attempt was thus made at establishing predictive factors conducive to better reaction to treatment with UPA. The aim of this study was to assess the efficacy of UPA treatment in women with myomas, depending on pretreatment myomas’ volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Materials and methods: The study included patients with one to four myomas. The UPA treatment was a preparation stage for surgical treatment in all patients. The study group was divided into the subgroups according to pretreatment myomas’ volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Results: A better effect of reduction in size of myomas after UPA treatment was noted when pretreatment myomas’ volume was lower than 30 cm(3). A significant reduction in fibroids’ size was observed after UPA therapy independently of the number of myomas and age of patients. A good response after the UPA therapy was observed when pretreatment estradiol concentration was below 50 pg/mL and when uterine artery resistance index (RI) was above 0.8. Conclusions: Our research demonstrates that treatment with ulipristal acetate is an efficient method in preoperative preparation of patients with uterine fibroids. The most important factor of positive response to UPA therapy is myoma volume. The number of myomas and patient’s age do not interfere with effects of UPA therapy. Pretreatment estradiol concentration is significant, yet secondary for the effects of therapy. The UPA therapy has no impact on blood flow in the uterine arteries and no adverse influence on estradiol concentrations. MDPI 2020-01-28 2020-02 /pmc/articles/PMC7037608/ /pubmed/32012826 http://dx.doi.org/10.3390/ijerph17030798 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szydłowska, Iwona Marciniak, Aleksandra Nawrocka-Rutkowska, Jolanta Rył, Aleksandra Starczewski, Andrzej Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids |
title | Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids |
title_full | Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids |
title_fullStr | Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids |
title_full_unstemmed | Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids |
title_short | Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids |
title_sort | predictive factors of response to selective progesterone receptor modulator (ulipristal acetate) in the pharmacological treatment of uterine fibroids |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037608/ https://www.ncbi.nlm.nih.gov/pubmed/32012826 http://dx.doi.org/10.3390/ijerph17030798 |
work_keys_str_mv | AT szydłowskaiwona predictivefactorsofresponsetoselectiveprogesteronereceptormodulatorulipristalacetateinthepharmacologicaltreatmentofuterinefibroids AT marciniakaleksandra predictivefactorsofresponsetoselectiveprogesteronereceptormodulatorulipristalacetateinthepharmacologicaltreatmentofuterinefibroids AT nawrockarutkowskajolanta predictivefactorsofresponsetoselectiveprogesteronereceptormodulatorulipristalacetateinthepharmacologicaltreatmentofuterinefibroids AT ryłaleksandra predictivefactorsofresponsetoselectiveprogesteronereceptormodulatorulipristalacetateinthepharmacologicaltreatmentofuterinefibroids AT starczewskiandrzej predictivefactorsofresponsetoselectiveprogesteronereceptormodulatorulipristalacetateinthepharmacologicaltreatmentofuterinefibroids |